{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:08:43Z","timestamp":1789006123673,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16304-8","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:30:21Z","timestamp":1782444621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immuno-oncology in the perioperative setting: the next frontier in resectable head and neck cancers \u2013 a systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Akhil","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipinesh","family":"Sansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal Krishna","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"12","key":"16304_CR1","doi-asserted-by":"publisher","first-page":"11234","DOI":"10.1002\/cam4.5815","volume":"12","author":"U Nindra","year":"2023","unstructured":"Nindra U, Hurwitz J, Forstner D, et al. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Med. 2023;12(12):11234\u201348. PMID: 36934434.","journal-title":"Cancer Med"},{"issue":"Suppl 1","key":"16304_CR2","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/crst.crst_124_23","volume":"7","author":"V Noronha","year":"2024","unstructured":"Noronha V, Prabhash K, Babu KG, et al. Indian clinical practice consensus guidelines for the management of very advanced head-and-neck squamous cell carcinoma: Update 2022. Cancer Res Stat Treat. 2024;7(Suppl 1):S31\u20135. https:\/\/doi.org\/10.4103\/crst.crst_124_23.","journal-title":"Cancer Res Stat Treat"},{"issue":"11","key":"16304_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.annonc.2025.07.004","volume":"36","author":"ZS Zumsteg","year":"2025","unstructured":"Zumsteg ZS, Luu M, Fortpied C, et al. Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501\/EORTC 22931. Ann Oncol. 2025;36(11):1379\u201388. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.004.","journal-title":"Ann Oncol"},{"issue":"19","key":"16304_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med."},{"issue":"10212","key":"16304_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-048). Lancet. 2019;394(10212):1915\u201328. PMID: 31679945.","journal-title":"Lancet"},{"key":"16304_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382\u201399.","journal-title":"Cancer Discov"},{"key":"16304_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2209","author":"J Friedman","year":"2019","unstructured":"Friedman J, Moore EC, Zolkind P, et al. Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen-specific T cells. Clin Cancer Res Published online. 2019. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2209.","journal-title":"Clin Cancer Res Published online"},{"key":"16304_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u201361.","journal-title":"Nat Med"},{"issue":"19","key":"16304_CR9","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus\u2013unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020;26(19):5140\u201352. PMID: 32665297.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16304_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med. 2025;393(1):37\u201350. PMID: 40532178.","journal-title":"N Engl J Med"},{"issue":"10526","key":"16304_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","volume":"407","author":"J Bourhis","year":"2026","unstructured":"Bourhis J, Aup\u00e9rin A, Borel C, et al. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet. 2026;407(10526):363\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(25)01850-1.","journal-title":"Lancet"},{"key":"16304_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. PMID: 33782057. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"16304_CR13","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919. PMID: 27733354.","DOI":"10.1136\/bmj.i4919"},{"key":"16304_CR14","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. PMID: 31462531.","DOI":"10.1136\/bmj.l4898"},{"issue":"6","key":"16304_CR15","doi-asserted-by":"publisher","first-page":"e002568","DOI":"10.1136\/jitc-2021-002568","volume":"9","author":"RL Ferris","year":"2021","unstructured":"Ferris RL, Spanos WC, Leidner R, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck (CheckMate 358). J Immunother Cancer. 2021;9(6):e002568. PMID: 34083421.","journal-title":"J Immunother Cancer"},{"key":"16304_CR16","unstructured":"Vos JL, Elbers JBW, Krijgsman O et al. Neoadjuvant nivolumab and ipilimumab induces major pathological responses in resectable head and neck squamous cell carcinoma (IMCISION trial). Nat Commun. 2021;12(1):7348. PMID: 34997127."},{"key":"16304_CR17","doi-asserted-by":"crossref","unstructured":"Ju WT, Xia RH, Zhu DW et al. A pilot study of neoadjuvant camrelizumab (anti\u2013PD-1) plus apatinib (anti\u2013VEGFR2) for locally advanced resectable oral squamous cell carcinoma. Nat Commun. 2022;13(1):5378. PMID: 36104359.","DOI":"10.1038\/s41467-022-33080-8"},{"issue":"15suppl","key":"16304_CR18","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1200\/JCO.2021.39.15_suppl.6011","volume":"39","author":"A Rosenberg","year":"2021","unstructured":"Rosenberg A, Agrawal N, Pearson AT, et al. Nivolumab, nab-paclitaxel, and carboplatin followed by risk\/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial. J Clin Oncol. 2021;39(15suppl):6011.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16304_CR19","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/annonc\/mdw428","volume":"27","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Geiger JL, Trivedi S, et al. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Ann Oncol. 2016;27(12):2257\u201362. https:\/\/doi.org\/10.1093\/annonc\/mdw428.","journal-title":"Ann Oncol"},{"issue":"5","key":"16304_CR20","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.21037\/tcr-20-2096","volume":"10","author":"TJ Hayman","year":"2021","unstructured":"Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Transl Cancer Res. 2021;10(5):2571\u201385. https:\/\/doi.org\/10.21037\/tcr-20-2096.","journal-title":"Transl Cancer Res"},{"issue":"5","key":"16304_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"JP Machiels","year":"2024","unstructured":"Machiels JP, Tao Y, Licitra L, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (KEYNOTE-412). Lancet Oncol. 2024;25(5):572\u201387. PMID: 38561010.","journal-title":"Lancet Oncol"},{"issue":"36","key":"16304_CR22","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.2217\/fon-2020-0595","volume":"16","author":"HB Zech","year":"2020","unstructured":"Zech HB, Moeckelmann N, Boettcher A, et al. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. Future Oncol. 2020;16(36):3035\u201343. https:\/\/doi.org\/10.2217\/fon-2020-0595.","journal-title":"Future Oncol"},{"key":"16304_CR23","doi-asserted-by":"publisher","unstructured":"Ferris RL, Gooding WE, Chiosea SI et al. Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer [Phase II Clinical Trial]. J Clin Oncol. 2023 (suppl 16; abstr 6018) https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.6018","DOI":"10.1200\/JCO.2023.41.16_suppl.6018"},{"key":"16304_CR24","doi-asserted-by":"crossref","unstructured":"Wong DJ, Fayette J, Teixeira M IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Presented at: 2024 AACR Annual Meeting; 2024; San Diego, CA. Abstract CT009.","DOI":"10.1158\/1538-7445.AM2024-CT009"},{"issue":"16suppl","key":"16304_CR25","doi-asserted-by":"publisher","first-page":"TPS6123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6123","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Guo W, Zhang W, et al. EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma. J Clin Oncol. 2024;42(16suppl):TPS6123. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS6123.","journal-title":"J Clin Oncol"},{"key":"16304_CR26","unstructured":"CTRI\/2024\/04\/065574. Tata Memorial Centre \u2013 Immunotherapy with metronomic chemotherapy (TMC-i study) in locally advanced oral cavity squamous cell carcinoma. Clinical Trials Registry- India. Available from: http:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=66574. Accessed 27 Aug 2025."},{"key":"16304_CR27","doi-asserted-by":"publisher","first-page":"175883592098406","DOI":"10.1177\/1758835920984061","volume":"13","author":"V Guti\u00e9rrez Calder\u00f3n","year":"2021","unstructured":"Guti\u00e9rrez Calder\u00f3n V, Cantero Gonz\u00e1lez A, G\u00e1lvez Carvajal L, et al. Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. Ther Adv Med Oncol. 2021;13:1758835920984061. https:\/\/doi.org\/10.1177\/1758835920984061.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"16304_CR28","doi-asserted-by":"publisher","first-page":"e2500194","DOI":"10.1200\/OA-25-00194","volume":"3","author":"A Kapoor","year":"2026","unstructured":"Kapoor A, Gupta A, Sansar B, Mishra BK, Kallapura G, Giridhar P, et al. Translational implications of microbiome testing methodologies in lung cancer: a systematic review of 16S rRNA sequencing, shotgun metagenomics, and short-chain fatty acid profiling. JCO Oncol Adv. 2026;3(1):e2500194. https:\/\/doi.org\/10.1200\/OA-25-00194.","journal-title":"JCO Oncol Adv"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16304-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:46:33Z","timestamp":1789004793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16304-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16304"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16304-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review of previously published articles. Ethics approval and consent to participate were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akhil Kapoor Research Funding: AstraZeneca (Inst), Novartis (Inst), Lilly (Inst), Biocon (Inst), Bayer (Inst), Johnson & Johnson\/Janssen (Inst), BMS (Inst), Pfizer (Inst). Anuj Gupta Research Funding: AstraZeneca (Inst), Lilly (Inst), Biocon (Inst), Bayer (Inst). Bipinesh Sansar Research Funding: AstraZeneca (Inst), Johnson & Johnson\/Janssen (Inst), BMS (Inst). Bal Krishna Mishra Research Funding: AstraZeneca (Inst), Pfizer (Inst). Vanita Noronha Research Funding: AstraZeneca (Inst), Merck (Inst), Novartis (Inst), Roche India (Inst), Johnson & Johnson\/Janssen (Inst), Nanobiotix (Inst). Travel, Accommodations, Expenses: ASCO Kumar Prabhash Research Funding: Biocon (Inst), Dr Reddy\u2019s Laboratories (Inst), Fresenius Kabi (Inst), Alkem Laboratories (Inst), NATCO Pharma (Inst), BDR Pharmaceutics (Inst), Roche (Inst), Aurigene Oncology Limited (Inst), Johnson and Johnson (Inst). No other potential conflicts of interest were reported.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1081"}}